 |
 |
 |
|
 |
The U.S healthcare system is under tremendous stress as a result of unsustainable cost pressures, demographic shifts and the advent of new medical technologies. By personalizing medicine through better understanding of the individual we can improve patient care and greatly increase healthcare productivity. MDV funds entrepreneurs and cross-disciplinary teams focused on biomedical breakthroughs, molecular diagnostics and technology platforms that will deliver on this vision. |
|||||||||||||||||||||||||||
 |
On-Q-ity is a next-generation diagnostics company focused on transforming cancer treatment and improving treatment outcomes for cancer patients. The company is developing innovative diagnostics to identify the unique characteristics of an individual's cancer, predicting the response to therapy, and monitoring the progress of treatment.
Pacific Biosciences (PacBio) is developing a transformative single-molecule, real-time (SMRT) DNA sequencing platform. PacBio's goal is to commercialize SMRT DNA sequencing technology, eventually enabling sequencing of individual genomes as part of routine medical care. Founded in 2004.
Adamas is an emerging pharmaceutical company focused on developing small molecule, Advantaged Therapeutics™ to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas' approach to pharmaceutical development is to identify and match proven drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care.
CardioDx is a molecular diagnostics company that serves cardiologists and their patients by offering clinically validated genomic tests to enhance patient care. These tests will help cardiologists identify patients who will benefit most from advanced cardiovascular therapies and predict risk for developing disease. Founded in 2004.
Corventis is focused on improving the care of cardiovascular patients and revolutionizing the treatment of cardiovascular disease by developing truly innovative and clinically meaningful technologies for health care professionals. Founded 2005.
iRhythm strives to ensure that cardiac rhythm monitoring becomes more accessible and available to patients who may be at risk for an abnormal heart rhythm, or an arrhythmia.
Navigenics, Inc. specializes in personalized consumer health and wellness services, with the overall goal of improving health outcomes in individuals across the population. Navigenics educates and empowers customers with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact.
RainDance Technologies™ is a provider of innovative droplet-based solutions that accelerate human health and disease research. The simplicity and speed of its new technology inspire researchers to rethink the way they design experiments and approach discovery. Its core RainStorm™ microfluidics technology produces 10 million picoliter-volume droplets per hour. Each droplet is the functional equivalent of a test tube and can contain a single molecule, reaction, or cell. The company empowers the scientist with solutions that minimize experimental error, provide simple, high-speed workflow, and generate accurate measurements. Founded in 2004. www.raindancetechnologies.com/
Tethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers - biomarkers - that provide a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. Founded in 2002
VitaPath Genetics develops molecular diagnostics to help patients and their doctors correct genetic mutations that can result in serious, but preventable, disease. The company's initial focus is a validated genetic test for spina bifida, a common birth defect that can be avoided with high dose folic acid therapy under the care of a physician.
> See more portfolio companies.
|
|
|
||||||||||||||||||||||||
 
      
|
|||||||||||||||||||||||||||
